Galectins as potential pharmacological targets in renal injuries of diverse etiology

Gu, Ming; Mei, Xianglin

doi:10.1016/j.ejphar.2020.173213

Cited by 8 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[35] Several preclinical studies have confirmed the Gal-3 overexpression in renal tissues as a consequence of various types of injury. [36,37] In the current study; T2DM in mice was induced by (i.p.) injection of NA/STZ.…”

Section: Discussionmentioning

confidence: 87%

Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic Mice

Mahmoud,

Abdel‐Razik,

Elrehany

et al. 2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is a significant global health concern with a high morbidity rate. Accumulating evidence reveals that Galectin‐3 (Gal‐3), a β‐galactoside‐binding lectin, is a biomarker in kidney diseases. Our study aimed to assess the advantageous impacts of modified citrus pectin (MCP) as an alternative therapeutic strategy for the initial and ongoing progression of DN in mice with type 2 diabetes mellitus (T2DM). The animal model has been split into four groups: control group, T2DM group (mice received intraperitoneal injections of nicotinamide (NA) and streptozotocin (STZ), T2DM+MCP group (mice received 100 mg/kg/day MCP following T2DM induction), and MCP group (mice received 100 mg/kg/day). After 4 weeks, kidney weight, blood glucose level, serum kidney function tests, histopathological structure alterations, oxidative stress, inflammation, apoptosis, and fibrosis parameters were determined in renal tissues. Our findings demonstrated that MCP treatment reduced blood glucose levels, renal histological damage, and restored kidney weight and kidney function tests. Additionally, MCP reduced malondialdehyde level and restored glutathione level, and catalase activity. MCP demonstrated a notable reduction in inflammatory and apoptosis mediators TNF‐α, iNOS, TGF‐βRII and caspase‐3. Overall, MCP could alleviate renal injury in an experimental model of DN by suppressing renal oxidative stress, inflammation, fibrosis, and apoptosis mediators.

show abstract

Section: Discussionmentioning

confidence: 87%

Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic Mice

Mahmoud,

Abdel‐Razik,

Elrehany

et al. 2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

show abstract

“…Hence, novel studies concerning anti-fibrotic therapeutic strategies have been sprung up in researches. Gal-1 is one of the members in the Galectin family and localized in cytomembrane and cytoplasm, which has been verified to exert a regulated role in cell proliferation, migration and growth (6,7). Importantly, Gal-1 was reported to be involved in angiogenesis via binding with N-glycans of vascular endothelial growth factor (VEGF) receptor 2 to further regulate the VEGF-A effect (8).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Galectin-1 attenuates lung fibroblast activation and proliferation in lung fibrosis

Jing Xue,

Shaojun Li

2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

“…Interestingly, the expression profile of galectins is altered during several pathological conditions (expert opinions for each disease have been reviewed in [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ]). In particular, the production of galectins-1, -3, -7, -8, and -9 is deregulated during tumorigenesis [ 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure

Laderach

Compagno

2021

Cancers

View full text Add to dashboard Cite

Current data indicates that anti-tumor T cell-mediated immunity correlates with a better prognosis in cancer patients. However, it has widely been demonstrated that tumor cells negatively manage immune attack by activating several immune-suppressive mechanisms. It is, therefore, essential to fully understand how lymphocytes are activated in a tumor microenvironment and, above all, how to prevent these cells from becoming dysfunctional. Tumors produce galectins-1, -3, -7, -8, and -9 as one of the major molecular mechanisms to evade immune control of tumor development. These galectins impact different steps in the establishment of the anti-tumor immune responses. Here, we carry out a critical dissection on the mechanisms through which tumor-derived galectins can influence the production and the functionality of anti-tumor T lymphocytes. This knowledge may help us design more effective immunotherapies to treat human cancers.

show abstract

Galectins as potential pharmacological targets in renal injuries of diverse etiology

Cited by 8 publications

References 57 publications

Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic Mice

Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic Mice

Inhibition of Galectin-1 attenuates lung fibroblast activation and proliferation in lung fibrosis

Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure

Contact Info

Product

Resources

About